Here, we present a protocol to perform a time-kill assay (TKA) to quantify bacterial burden at multiple time points using colony-forming units and most probable number readouts simultaneously. We describe steps for preparing inoculum, experimental conditions, and sampling bacterial counts. We then detail procedures for quantification and analysis. TKAs provide longitudinal data reflecting the dynamics of the antibiotic effect over time against a planktonic culture and quantify the concentration-effect relationship. For complete details on the use and execution of this protocol, please refer to Van Wijk et al.1.
5 August 2026 in Antimicrobial Agents and Chemotherapy
GSK2556286 (GSK286) is a novel drug candidate with a cholesterol-dependent mode of action that has shown promising in vivo potential to improve tuberculosis treatment when combined with bedaquiline (B) and pretomanid (Pa). This study explored the in vitro activity of GSK286 alone and in combination with B and Pa, using extracellular and intracellular dose-response time-kill assays against different Mycobacterium tuberculosis (Mtb) strains. GSK286 demonstrated media-specific activity, inhibiting Mtb growth only in cholesterol- and propionate-containing media, with slight activity against both extracellular and intracellular Mtb. The Mtb strain overexpressing Mtb adenylyl cyclase Rv1625c exhibited higher susceptibility to GSK286, whereas the Rv1625c mutant was more resistant. This confirms GSK286’s mechanism of action linked to Rv1625c . GSK286 combined with BPa was bactericidal, although the main driver of this interaction was observed between GSK286 and B, with potency comparable to that of the triple BPa + GSK286 regimen, both extracellularly and intracellularly. These findings suggest that GSK286 may be a promising companion to B, with or without Pa, particularly under conditions with a sub-optimal B dose, where the GSK286 + B interaction was more clearly observed. These studies offer new insights into this drug combination to guide future research toward better tuberculosis treatments.
The first-in-class diarylquinoline (DARQ) bedaquiline (BDQ) is in the medicines list for drug-resistant tuberculosis. TBAJ-587 is a next-generation DARQ with improved anti-Mycobacterium tuberculosis (Mtb) activity and reduced cardiac repolarization abnormalities. Methods. The in-vitro efficacy of TBAJ-587 and its main metabolites (M2, M3 and M12) was analyzed under standard (ST) growth conditions, with cholesterol (CHO), or fatty acids (FA) as alternative carbon sources. Minimal inhibitory concentration (MIC) assays and time-kill assays (TKA) linked to drug measurements in bacterial samples were performed to allow correlation of pharmacodynamics (PD) with actual pharmacokinetics (PK). The most active compounds, TBAJ-587 and its M3 metabolite, exhibited broth media and concentration dependent efficacy showing a bactericidal effect at ≥5x MIC. Bacterial cultures treated with 1x MIC and 2x MIC of TBAJ-587 resumed growth after 28 days and displayed moderate increased MIC values compared to untreated conditions, which were linked to new variants of BDQ resistance mutations in the atpE, atpB, and Rv0678 genes. This study revealed TBAJ-587 and metabolites bind to polystyrene plastic-ware, the most commonly used material in antimicrobial research, being the effective unbound drug concentration dependent on the media composition. PKPD analyses determined that Mtb was killed with lower exposures of TBAJ-587 and M3 than expected in ST and FA broth, suggesting previously underestimated potency in these media. This is the first in-vitro study to precisely link compound activities (PD) to their effective concentration (PK) over time in Mtb cultures, providing improved longitudinal data to feed models for translational research.